POLD3

Across TCGA pan-cancer cohorts, POLD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POLD3 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher POLD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POLD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where POLD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.547	0.930	<.001	70	view →
LSCC	DFS	Median	II,III,IV	0.858	0.514	.004	19	view →
HNSC	DFS	Median	All	0.698	1.000	.020	15	view →
LUAD	DFS	Median	III,IV	0.947	0.570	.002	11	view →
PDAC	DFS	Tertile	IV	0.741	0.203	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POLD3–CCRCC (OS)

Open the CCRCC breakdown →